The European Society for Medical Oncology (ESMO) Congress 2025 convened leading oncology experts to share advances shaping cancer care worldwide. Fast Five coverage captured key insights presented live from the meeting.
Elizabeth Buchbinder, Assistant Professor of Medical Oncology at Dana-Farber Cancer Institute, highlighted developments across cutaneous and uveal melanoma, focusing on updated guideline recommendations, emerging cellular therapies and data with potential practice-changing impact.
ESMO guideline updates for cutaneous melanoma emphasize refined recommendations for systemic therapy selection, adjuvant treatment strategies, surveillance and multidisciplinary management to support individualized patient care.
Phase I results from the IMA203 trial of PRAME-directed T cell therapy in uveal melanoma reported an acceptable safety profile and early signs of antitumor activity, signaling a potential new approach for a disease with limited systemic treatment options.
PRAME-targeted T cell therapy could alter the uveal melanoma treatment landscape by offering a tumor-directed cellular option; further trials will be required to confirm efficacy, define patient selection criteria and assess durability of response.
Emerging trends to watch include expanded use of cellular therapies, combination immunotherapy strategies, biomarker-driven treatment selection and increasingly personalized approaches across melanoma subtypes.
The newly published EMJ Oncology Journal presents comprehensive ESMO 2025 coverage, featuring expert interviews, peer-reviewed articles and a visual infographic summarizing key findings.
Leave a Reply